Fairvalue-Calculator Fairvalue-Calculator
EN DE

Codexis, Inc (CDXS) Fair Value & Analysis

Healthcare · US · Market cap $234M

Price$2.39
Fair Value$2.50
Upside+4.6%
Quality95/100
Evidence: Low Range $1.88 – $3.13

Fair value as of: Jun 24, 2026

Analysis

Codexis, Inc (CDXS) currently trades at $2.39, while our model-based Fair Value estimate is $2.50 — implying the stock looks roughly 4.6% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Codexis, Inc (CDXS) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $2.50 versus a price of $2.39 — about +5% (undervalued). Model-based estimate, not financial advice.
What is the fair value of CDXS?
Our 21-model fair value for Codexis, Inc is $2.50 (as of Jun 24, 2026), built from audited fundamentals. The current price is $2.39.
What is the quality score of CDXS?
Codexis, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.